Stock Watch: Bayer’s Movable Goalposts
Lowered Full-Year Guidance Met After November’s Revision
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
